A streamline procedure allows treatment with the NanoTherm therapy system for focal ablation to be completed within 1 day.
Patient treatment has been completed in the initial part of stage 2 of a pivotal trial of the NanoTherm therapy system for the focal ablation of intermediate-risk prostate cancer, according to MagForce AG, the developer of the therapy.1